- Time:
Over the last two decades, immunotherapy has emerged as a key treatment for various cancers, though its benefits are limited to certain patients and often accompanied by significant toxicity. Advances in biomarkers related to the tumor immune microenvironment hold promise for improving precision immuno-oncology. Predictive biomarkers, such as PD-L1 expression, microsatellite instability-high, and tumor mutational burden (TMB), help identify patients likely to respond to immunotherapy, though challenges in standardization and testing persist.
Join Heidi Ko, DO, and RJ Seager, PhD, from Labcorp Oncology’s Medical Affairs team to learn about the current state of biomarker testing for immunotherapy decisions along with gaps and areas for opportunities to better identify the appropriate patient for treatment. These experts will review the role of emerging immune-related biomarkers of TIGIT, LAG3, and cancer-testis antigen burden (CTAB) in immunotherapy treatment decisions using the latest data describing the immunogenic profiles of various solid tumor types using comprehensive genomic and immune profiling (CGIP).
This Inside Precision Medicine webinar will provide insights into the practical use of these biomarkers through case studies and ongoing clinical studies incorporating these novel biomarkers for innovative immunotherapeutic developments.
Participants will learn to:
Recognize the role of comprehensive genomic and immune profiling (CGIP) in identifying novel biomarkers of tumor immune microenvironment that have the potential to predict responses to immunotherapy
Identify challenges of current biomarker selection for immunotherapy decisions
A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.
Produced with support from:
